Detailed description page of ThPDB2

This page displays user query in tabular form.

Th1230 details
Primary information
ID10870
Therapeutic IDTh1230
Protein NameHuman Varicella-Zoster Immune Globulin
SequenceNA
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting pointNA
Half-lifeHuman Varicella-Zoster Immunoglobulin has a half-life of about 18-24 days following intravenous administration and 24-30 days following intramuscular administration.
DescriptionHuman Varicella-Zoster Immune Globulin is a solvent/detergent-treated sterile liquid preparation of purified human immune globulin G (IgG) containing antibodies to varicella zoster virus (anti-VZV).
Indication/DiseaseIndicated for reducing the severity of chicken pox (varicella zoster virus) infections in high risk individuals after exposure
PharmacodynamicsProvides passive immunization for nonimmune individuals exposed to varicella zoster virus, thereby reducing the severity of varicella infections
Mechanism of ActionNA
ToxicitySince the drug was prepared from human plasma pool, it may contain other infectious agents such as viruses and Creutzfeldt-Jakob disease (vCJD) agent. Hypersensitivity reactions such as allergic or anaphylactic reactions may occur. More common adverse effects include pain at injection site, headache, and rash. Rare adverse effects from immune globulin intravenous therapy include thrombotic events, renal dysfunction and acute renal failure, and noncardiogenic pulmonary edema. An LD50 was not determined, as the maximal dose used did not kill any experimental animals.
MetabolismImmune globulins are metabolized in the reticuloendothelial system.
AbsorptionIntravenous administration of varicella zoster antibodies tends to persist for 6 weeks or longer. Following intramuscular administration of varicella immune globulin products, varicella antibodies are detectable within 2-3 days. The peak levels of varicella antibodies is expected to occur within 3-7 days of VariZIG administration.
Following intravenous administration of varicella zoster VZIG, anti-varicella zoster antibodies are expected to be quickly distributed between plasma and extravascular spaces with complete and immediate bioavailability. Intramuscular administration achieves nearly 100% bioavailability.
ClearanceNA
CategoriesAntibody
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionThe passive transfer of antibodies with immune globulin administration may impair the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella
Targetvaricella zoster virus
Brand NameVARIZIG
CompanyNA
Brand DescriptionNA
Prescribed ForIt is indicated for post-exposure prophylaxis of varicella in high risk individuals.
Chemical NameNA
FormulationIt is available in a single-use vial of 125 IU. Each 125 IU vial of VARIZIG contains less than 156 milligrams of total protein, mostly human immune globulin G (IgG). VARIZIG contains no preservative
Physical Appearance lyophilized powder for solution
Route of AdministrationIntramuscular
Recommended DosageDepending on patient size, divide the IM dose and administer in 2 or more injection sites; not to exceed 3 mL/injection site
ContraindicationHypersensitivity to human immunoglobulins
Side EffectsThe most common adverse drug reactions (reported by ≥ 1% of subjects) observed in clinical trials for all subjects and patients (n=601) are the following:injection site pain (3%),headache (2%),rash (including terms pruritus, rash, rash erythematous, rash vesicular and urticaria) (1%),fatigue (1%),chills (1%),nausea (1%)
Useful Link 1Link
Useful Link 2NA
RemarksNA